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predominantly positive. However, experts refer to methodological deficits and only 
few would recommend the use of the instruments in practice. ConClusions: 
There are many questionnaires to assess workability and related concepts. 
However, only few seem to be scientifically sound and valid and at the same time 
applicable for a broad use in practice.
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objeCtives: Identify the principal challenges faced during migration from paper 
to electronic platform when placeholders are used within translated content, as 
eCOA questionnaires will often use placeholders which are replaced by other 
words/numbers when the software is running (string concatenation) Methods: 
110 reviews across 22 languages were collated; languages facing issues with place-
holders were identified; problems and resolutions were compared and results 
were reviewed in order to identify patterns. Results: Just over 40% of languages 
had issues with the population of software placeholders. Two main problems 
were found: (1) Issues involving articles and pronouns (including use of multiple 
articles/neutral pronouns/other gender agreements) – For example, Italian uses 
articles (al/alla) before a noun, so when a noun of either gender is electronically 
inserted into a sentence, the simplest resolution was to include all variations of 
the article before every placeholder. However in French where 3 kinds of article 
were required the result was too long, and a gender-neutral pronoun was used. 
(2) Some languages use two or more noun cases which raised issues. For example, 
Czech nouns change form depending on how they’re used in sentences but the 
running software inserted the same form of the noun everywhere. It was decided 
that the auto-populated text would be altered to fit the majority of cases, and 
instances which were an exception would be replaced with static text to ensure 
they appeared correctly. ConClusions: There are frequently issues with string 
concatenation that require in-depth discussion, as very few languages function 
in the same way as English. However, the issues that arose here could be resolved 
with careful consideration between the lead linguist and the project manager. 
All challenges were dealt with on an individual basis to attain a translation that 
reflects the source in the most natural way possible whilst still remaining true 
to the source.
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objeCtives: Patient-Reported Outcome (PRO) instruments are increasingly 
being utilized in drug development to provide a holistic understanding of the 
drugs impact. Such data can be beneficial in clinical decision making. This review 
sought to identify and discuss the PRO instruments used in Phase 3 trials of the 
newer classes of drugs for the treatment of Type 2 diabetes (T2DM). Methods: A 
search was conducted in medline, psychinfo, cinahl, and clinicaltrials.gov using 
17 drug names contained within the following classes: GLP-1 receptor agonists, 
novel insulins, SGLT-2 inhibitors, and DPP-4 inhibitors. This search was supple-
mented with EASD and ADA abstract database searches from 2012-2014. PRO 
instruments used in Phase 3 trials were identified and categorized by measure-
ment concept(s). The items and domains contained within the PRO instruments 
were further explored and summarized. Results: Twenty PRO instruments have 
been used, although none in DPP-4 inhibitor trials. PRO instruments were used 
to measure six separate concepts: treatment satisfaction (10/17 drugs), health-
related quality of life (HRQoL) (8/17), impact of weight/eating-related outcomes 
(6/17), symptoms of diabetes (3/17), psychological well-being (3/17), and cogni-
tive functioning (1/17). Although several PRO instruments were used to measure 
the same concept, the items and domains that comprised that concept differed 
across instruments. For example, only two of the seven treatment satisfaction 
questionnaires contain items pertaining to the injectable therapy device. In addi-
tion, some PRO instruments did not comprehensively evaluate the concept that 
they claimed. For example, an item-level analysis of the EQ-5D, identified as a 
measurement of HRQoL, suggests that it more accurately measures functional 
health status, thereby representing only one dimension of HRQoL. ConClusions: 
PRO data are available for many recently approved drugs in T2DM. More work 
is needed to highlight the relevance and importance of PRO data from pivotal 
trials as an important consideration for physicians when making treatment 
decisions.
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objeCtives: To develop a checklist of essential items, which authors should con-
sider when reporting studies of mapping to preference-based measures from other 
outcome measures. The aim of the checklist (the MApping onto Preference-based 
measures reporting Standards (MAPS) statement) is to promote complete and trans-
parent reporting by researchers. Methods: A working group of health economists 
and a Delphi methodologist was convened. Candidate items for the checklist were 
identified through a structured review of the literature and reviewed by the working 
group. A modified Delphi survey, with representatives from academia, consultancy, 
health technology assessment agencies and the biomedical journal editorial com-
munity, was used to identify a list of essential reporting items from the set of can-
with MTX alone or in combination, to explore their experience. Qualitative analysis 
was performed to develop a conceptual model of the factors influencing adher-
ence to MTX. Based on this model, items were generated using patients’ verbatim, 
and comprehension tested with 18 RA patients. Acceptability and applicability of 
the resulting pilot version were then assessed in clinical practice during consul-
tation, with 10 rheumatologists, using the PRAgmatic Content and face validity 
Test. Results: Several factors associated with poor adherence to MTX were elicited 
from the analysis of the exploratory interviews: barriers (practical, physical, emo-
tional, cognitive, financial), side effects, treatment perceived efficacy; doctor-related 
factors, patients’ beliefs, expectations and behaviors towards treatment, and exter-
nal sources. The resulting MTX Adherence Questionnaire included 29 questions, plus 
three about MTX administration mode and dose, divided into 5 sections: “Practical 
aspects of MTX”; “Me and MTX”; “Efficacy of MTX”; “My feelings about MTX”; “My 
opinion regarding my care”; “MTX treatment in general”. Rheumatologists accepted 
very well the questionnaire and found it useful to enhance communication with 
their patients (n= 8/10). ConClusions: The MTX Adherence Questionnaire is a 
patient self-administered tool that identifies patients facing adherence issues with 
MTX, and thereby helps clinicians make better-informed treatment decisions. It is 
suitable for use in clinical practice. A validation study to assess its robustness in 
research and clinical practice is being set up.
PRM184
the Most FRequent FeARs AnD belieFs oF 226 PAtients with 
RheuMAtoiD ARthRitis oR sPonDyloARthRitis, using A novel 
questionnAiRe
Gossec L1, Chauvin P2, Hudry C3, Mathoret-Philibert F3, Poussière M4, de Chalus T5, Russo-
Marie F6, Joubert J7, Saraux A8, Berenbaum F9
1Sorbonne Universités, Université Pierre et Marie Curie, AP-HP, Hôpital Pitié Salpêtrière, Paris, 
France, 2French National Institute of Health and Medical Research (INSERM), Paris, France, 3AP-
HP Hôpital Cochin, Paris, France, 4Independent Researcher, Paris, France, 5UCB Pharma, Colombes, 
France, 6Arthritis Fondation Courtin, Neuilly-sur-Seine, France, 7UCB Pharma, Paris, France, 8CHU 
de la Cavale-Blanche, Brest Cedex, France, 9Sorbonne Universités, Université Pierre et Marie Curie, 
AP-HP, Hôpital Saint-Antoine, Paris, France
objeCtives: Patients with chronic inflammatory disorders, such as rheumatoid 
arthritis (RA) or spondyloarthritis (SpA), have personal sets of fears and beliefs 
related to their disease that may influence the patient-physician relationship and 
treatment adherence. The objective was to describe the most frequent fears and 
beliefs in RA and SpA patients. Methods: Cross-sectional assessment of unse-
lected patients with a diagnosis of RA (ACR/EULAR criteria) or axial SpA (axSpA)
(ASAS criteria) in France in 2014. The study was proposed to all rheumatologists in 
France. A self-reported 44-item questionnaire (25 items on fears, 19 on beliefs) was 
built and preliminarily validated for this study. Each item was scored 0–10 (10 indi-
cating higher fears/stronger beliefs). The analysis was descriptive for the 5 fears and 
5 beliefs most frequently scored as ≥ 7/10, in both axSpA and RA patients. Results: 
Overall, 226 patients (161 RA, 65 axSpA; 64.4% female) were analyzed: mean dis-
ease duration 11.9 vs 13.8 years and mean patient’s global assessment 31/100 vs 
41/100 for RA vs axSpA patients, respectively. Of the 25 listed fears, the 6 most 
frequently reported were: “afraid of suffering again” (66.7% scored this as ≥ 7/10), 
“afraid of losing control and autonomy” (61.4%), “afraid of being a burden for rela-
tives” (59.6%), “afraid of losing all joint mobility” (58.9%), “afraid of the spread of 
the disease to other joints” (58.6%) and “afraid of the consequences of my disease 
on my professional activity” (58.6%). Of the 19 listed beliefs, the 5 most frequently 
reported were: “flares are triggered by fatigue” (41.7%), “physical activity reduces 
flares” (38.7%), “flares are triggered by changes in the weather” (37.3%), “flares are 
triggered by physical effort” (37.1%) and “the disease is linked to a genetic cause” 
(36.9%). ConClusions: This study highlights the main fears and beliefs from a 
patient perspective using a novel questionnaire specific to chronic inflammatory 
arthritis.
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objeCtives: Currently there is no standardized tool or questionnaire to measure 
workability and related concepts. Instead, there are various different instruments 
researchers and practitioners can choose between. However, a comprehensive 
review is still lacking and there is no evidence which instruments are used in prac-
tice. The objective of this paper is to identify, describe and evaluate the existing 
instruments for measuring workability, presenteeism, productivity and related 
concepts and to assess the status quo regarding the use and awareness of the 
instruments in Germany. Methods: We adopted a 2-step-approach: (1) PubMed, 
the Cochrane Library and ScienceDirect were searched for relevant articles pub-
lished before August 2014. Internet search and scanning reference lists comple-
mented our search. Two authors independently reviewed titles, assessed articles’ 
eligibility and extracted relevant data. Instruments identified in literature were 
briefly described and evaluated. (2) Experts from rehabilitation, health manage-
ment/economics and representatives of the medical profession were interviewed 
on their experiences with measuring workability. The survey was based on a 
semi-standardized, structured guideline and conducted by telephone. Results: 
(1) Systematic review revealed 4665 articles. Thereof 357 were included in further 
research. In total, we identified 57 instruments (including different versions of 
single instruments). Instruments vary significantly regarding content, response 
format, length, etc. Instruments most often used include WPAI, WLQ, SPS, HPQ, 
HLQ, WAI and MIDAS. (2) Results of the interviews indicate that the WAI and WPAI 
are the instruments most common and also most often used in Germany. Both 
tools are considered appropriate for measuring workability and experiences are 
